New theranostic agents show efficacy in prostate cancer treatment in preclinical studies

Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies. The agents, which target prostate-specific membrane antigen (PSMA), can be easily and economically synthesized without specialized equipment. This research was presented at the Society of Nuclear Medicine and Molecular Imaging’s 2020 Annual Meeting on July 11-14, 2020.